Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial

Abroad (travel likely)RecruitingPHASE2

Conditions

Meningioma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

CHRU of Nancy, Vandœuvre-lès-Nancy, Grand Est, France
Contact: Study coordinator (Anne-Sophie Hue) · dripromoteur@chru-nancy.fr
Contact: Principal Investigator (Antoine Verger, PhD)
Achraf Bahloul, MD (Sub-investigator)
Marie Pierre-Yves, PhD (Sub-investigator)
Nancy Hospital, Vandœuvre-lès-Nancy, France
Contact: Study coordinator (Antoine Verger, MD PhD) · a.verger@chru-nancy.fr · +33383155567
Contact: Study coordinator (Anne-Sophie Hue) · a.hue@chru-nancy.fr · +33383153475

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

NEO100 and High-Grade Meningioma

Residual, Progressive or Recurrent Grade II or III Meningioma

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States · San Francisco, United States

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Meningioma

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Phoenix, United States

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Intracranial Meningioma · Recurrent Meningioma · NF2 Gene Mutation

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Anchorage, United States

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Recurrent Meningioma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Columbus, United States